Minimal Residual Disease Testing
Jun 25, 2026
Legacy Expands Diagnostic Portfolio with New York CLEP Approval for Two LDTs; Quest Diagnostics Expands Patient Access to ctDNA MRD Testing with New York Approval of Haystack MRD; MVZ MedDiagnost and Sectra Ink 10-Year Deal to Unify Radiology Network Across 10 Sites; ALZpath and Abbott Enter Global Licensing Deal to Expand Blood-Based Alzheimer’s Diagnostics; Corvention Reaches Key Commercial Milestone with First U.S. Procedure and Balloon Catheter Launch; ZETA SURGICAL® Achieves First Clinical Milestone with Initial Patient Treatment at HOPE Therapeutics
Legacy Received New York State CLEP Approval for Two Laboratory-Developed Tests: Semen Analysis and DNA Fragmentation On 24 June 2026, Legacy announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, had validated and approved it...
Read More...
Feb 05, 2026
GE HealthCare Secures FDA 510(k) Clearance and CE Mark for Allia Moveo, Completing First Global Installation; China NMPA Approves Promega’s MSI Test as a Companion Diagnostic for KEYTRUDA; Oracle Life Sciences AI Data Platform Unifies Data and Agentic Intelligence to Accelerate Breakthroughs and Boost Commercial Outcomes; Quest Diagnostics Launches New Blood Test for Detecting Minimal Residual Myeloma; RevBio Secures FDA Clearance to Begin Pivotal Study of Cranial Bone Glue; Hyperfine Reports Breakthrough Clinical Findings on Swoop® System’s Increased Sensitivity in Stroke Detection
GE HealthCare Announced the U.S. FDA 510(k) Clearance and CE Mark for Allia Moveo and marks first Global Installation, Advancing Precision Care in the Interventional Suite On February 02, 2026, GE HealthCare announced that Allia™ Moveo received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
